



TISOTUMAB VEDOTIN

An investigational antibody-drug conjugate directed to tissue factor

Anti-tissue factor antibody


Fully human monoclonal antibody that binds to tissue factor

MMAE

Microtubule-disrupting agent

Protease-cleavable mc-vc linker

Covalently attaches MMAE to the antibody and releases agent upon internalization into target cells



Directed to: Tissue Factor

- Physiological function of tissue factor can be co-opted by tumor cells to promote tumor growth, angiogenesis and metastasis^{1,2}
- High prevalence in several solid tumors, including cervical cancer, and HNSCC^{3,4}

Proposed Mechanism of Action^{5-8,a}

- Direct cytotoxicity
- Bystander effect
- Antibody-dependent cellular cytotoxicity
- Antibody-dependent cellular phagocytosis
- Immunogenic cell death

HNSCC: head and neck squamous cell carcinoma; **mc-vc:** maleimidocaproyl-valine-citrulline; **MMAE:** monomethyl auristatin E

^aBased on preclinical data

1. van den Berg YW. Blood. 2012; 924-32. 2. Forster Y. Clin Chim Acta. 2006; 12-21. 3. Cocco E. BMC Cancer. 2011; 263. 4. Cocco E. Clin Exp Metastasis. 2011; 689-700. 5. Alley SC. Cancer Res. 2019; Abstract 221. 6. De Goeij BECG. Mol Cancer Ther. 2015; 1130-40. 7. Breij EC. Cancer Res. 2014; 1214-26. 8. Gray E. SITC virtual 2020: Abstract 617.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.



Scan to learn more about the proposed mechanism of action of tisotumab vedotin

Clinical Trials^a

Phase 1 Phase 2 Phase 3



RECRUITING

innovaTV 301: Recurrent or metastatic cervical cancer (NCT04697628)
Tisotumab vedotin vs investigator's choice chemotherapy



RECRUITING

innovaTV 207^b: Advanced solid tumors (NCT03485209)
Tisotumab vedotin



ACTIVE,
NOT
RECRUITING

innovaTV 205^{b,c}: Recurrent or metastatic cervical cancer (NCT03786081)
Tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin

^aProgram being co-developed with Genmab A/S

^bTrial in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD)

^cPhase 1b/2

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.